Sartorius reviews fiscal 2014 results
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, closed fiscal 2014 with significant gains in sales revenue and earnings.
List view / Grid view
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, closed fiscal 2014 with significant gains in sales revenue and earnings.
2 March 2015 | By Roche
Roche announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc...
2 March 2015 | By Otsuka Pharmaceutical Co. Ltd
Otsuka Pharmaceutical Co., Ltd. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended JINARC® (tolvaptan) for approval...
2 March 2015 | By Amgen
Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the marketing authorization for Vectibix® (panitumumab) to include combination with FOLFIRI (an irinotecan-based chemotherapy) as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer (mCRC)...
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
27 February 2015 | By Gilead Sciences
First TAF-based regimen found to be non-inferior with improved renal and bone parameters compared to stribild®...
27 February 2015 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia® (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib...
27 February 2015 | By Moberg Pharma
Successful fourth quarter and the first profitable full year...
27 February 2015 | By UCB
"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient solutions: brivaracetam, epratuzumab and romosozumab..."
27 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient population that historically has been challenging to treat in large part due…
27 February 2015 | By GlobalData
Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country’s aging population, according to research and consulting firm GlobalData...
Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most effective at developing and commercialising new medicines – bringing innovations to market successfully.
26 February 2015 | By GAFFI
Early detection and treatment of fungal meningitis and pneumonia can save hundreds of thousands of lives, for a cost of 'only $30' per HIV patient, the world's first stakeholder meeting on fungal diseases hosted by GAFFI (Global Action Fund for Fungal Infections) and held in Seattle, USA has concluded...
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients...
26 February 2015 | By GlobalData
The global market for atrial fibrillation (AF) treatment will more than double in value from $4.6 billion in 2013 to peak sales of $9.4 billion in 2020, before declining to $5.7 billion by 2023 as new oral anticoagulants (NOACs) become genericized, according to research and consulting firm GlobalData...